Recent news includes the company's announcement to explore strategic alternatives in AI and quantum computing, completion of preclinical studies, and regulatory approval for Phase II clinical trials. The company has also undergone a reverse stock split and ownership consolidation by Trafalgar Asset Management.

• Greater Cannabis Company announced plans to explore strategic alternatives in artificial intelligence and quantum computing as of January 2, 2025 [N8].
• The company completed preclinical studies for its neuropsychiatric cannabinoid therapy as of February 27, 2024 [N8].
• Received approval from the Israel Ministry of Health to proceed with a Phase II clinical trial targeting autism-related spectrum disorders as of July 5, 2023 [N8].
• Underwent a 1-for-1,500 reverse stock split effective October 16, 2025, and created Series B Convertible Preferred Stock [S1].
• Trafalgar Asset Management, LLC acquired 100% of Series A and Series B Preferred Stock, controlling approximately 96.62% of voting power as of June 29, 2026 [S15].

The company has established exclusive licensing agreements for innovative cannabinoid therapeutics and delivery platforms, including a novel therapy targeting neuropsychiatric disorders. It has completed preclinical studies and received regulatory approval to initiate a Phase II clinical trial, indicating progress in clinical development. The company's control by a strategic investor and exploration of alternatives in AI and quantum computing suggest potential for strategic repositioning or partnerships.

The company faces significant liquidity constraints with minimal cash relative to current liabilities, indicating financial risk. The Phase II clinical trial is delayed pending sourcing of specialized APIs and requires additional funding, which may be challenging. The regulatory environment for cannabis remains complex and uncertain due to federal illegality. The company has limited operational scale with only one full-time employee and has undergone a substantial reverse stock split, which may reflect financial restructuring needs.

The company's moat is based on its exclusive worldwide license for a transmucosal patch platform for cannabis drug delivery and its license of a novel cannabinoid therapeutic from a reputable Israeli medical center. The involvement of a renowned cannabis researcher and the focus on neuropsychiatric disorders provide specialized intellectual property and clinical development pathways. However, the company currently has limited operational scale, a single full-time employee, and faces significant regulatory and funding challenges, which constrain its competitive position.

• Regulatory Risk: Cannabis remains a Schedule I controlled substance under federal law, creating legal and operational risks despite state-level legalization. Changes in enforcement or regulations could adversely affect the company's operations [S1].
• Liquidity and Funding Risk: The company has very low liquidity with a current ratio of 0.01 as of June 30, 2026, and requires additional funding to proceed with its Phase II clinical trial [S2].
• Clinical Development Risk: The Phase II clinical trial is pending due to difficulties sourcing specialized active pharmaceutical ingredients and requires successful trial completion and regulatory approvals for commercialization [S1].
• Operational Scale Risk: The company has only one full-time employee, the CEO, which may limit operational capacity and execution [S1].
• Market and Competitive Risk: The cannabinoid therapeutics market is competitive with other companies developing cannabis-based products and delivery methods, including Jazz Pharmaceuticals and Zynerba Pharmaceuticals [S1].

• Greater Cannabis Company, Inc. was formed in March 2014 and acquired Green C Corporation in July 2018, which is the accounting acquirer and the main operating entity since then [S1].
• The company shifted its business model in 2018 to focus on development and commercialization of innovative cannabinoid therapeutics [S1].
• It owns an exclusive worldwide license for an eluting transmucosal patch platform for non-invasive drug delivery in the cannabis field [S1].
• From 2018 to mid-2021, the company focused on commercializing transmucosal and transdermal delivery technologies for legal medical or recreational cannabis [S1].
• In October 2021, the company entered a license agreement with Shaare Zedek Scientific Ltd. for a novel cannabinoid therapeutic targeting autism, schizophrenia, Parkinson's, Alzheimer's, and other neuropsychiatric disorders [S1].
• The license agreement includes annual fees starting in the third year from June 21, 2021, milestone payments tied to clinical trial phases and regulatory approvals, and royalties on dietary supplement and drug product sales [S1].
• The company completed preclinical studies as of February 27, 2024, and received approval from the Israel Ministry of Health to proceed with a Phase II clinical trial as of July 5, 2023 [S1].
• The Phase II clinical trial is planned for 18 to 24 months duration, but the company is awaiting sourcing of specialized active pharmaceutical ingredients (API) to proceed and needs to raise additional funds for the trial [S1].
• The company filed a 1-for-1,500 reverse stock split effective October 16, 2025, and created a new class of Series B Convertible Preferred Stock [S1].
• As of June 29, 2026, Trafalgar Asset Management, LLC owns 100% of the Series A and Series B Preferred Stock, controlling approximately 96.62% of voting power [S15].
• The company has one full-time employee, the CEO [S1].
• The cannabis industry is subject to complex regulatory risks, including federal illegality under the Controlled Substances Act despite state-level legalization in many states [S1].
• The company reported net income of $611,378 and basic and diluted EPS of $0.61 for the quarter ended June 30, 2026 [S2].
• Cash and cash equivalents were $111 as of June 30, 2026, with current liabilities of $12,239, resulting in a current ratio of 0.01 and cash ratio of 0.01, indicating liquidity constraints [S2].
• The company has announced plans to explore strategic alternatives in artificial intelligence and quantum computing as of January 2, 2025 [N8].